Leveron&Nexovas
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 9400  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  » Next article
  » Previous article 
  » Table of Contents
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
  »  Article in PDF (46 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  References

 Article Access Statistics
    Viewed5037    
    Printed152    
    Emailed0    
    PDF Downloaded71    
    Comments [Add]    

Recommend this journal

 


 
INVITED COMMENTS
Year : 2005  |  Volume : 53  |  Issue : 3  |  Page : 302

Invited Comments


Dept. of Neurology, Bispebjerg Hospital, DK-2400 Copenhagen NV, USA

Correspondence Address:
Gudrun Boysen
Dept. of Neurology, Bispebjerg Hospital, DK-2400 Copenhagen NV
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions



How to cite this article:
Boysen G. Invited Comments. Neurol India 2005;53:302

How to cite this URL:
Boysen G. Invited Comments. Neurol India [serial online] 2005 [cited 2023 Jan 29];53:302. Available from: https://www.neurologyindia.com/text.asp?2005/53/3/302/16984


This study shows that hyperhomocysteinaemia is associated with an increased risk of stroke in India as has been shown in many other countries in the world. Elevated homocysteine is a risk factor for stroke both in the young[1] and in the elderly,[2] as well as for recurrent stroke.[3] Numerous studies have shown that supplementation with folate, vitamin B6, and B12 reduces the level of homocysteine. Intervention studies have so far been disappointing in being unable to show a reduced risk of stroke and cardiovascular events in vitamin B-treated groups,[4],[5] however, the results of many ongoing randomized trials are awaited with great expectations.[6] In the meantime, however, it is tempting to recommend vitamin supplementation for patients with highly elevated homocysteine levels.



 
 » References Top

1.Bos MJ, van Goor ML, Koudstaal PJ, Dippel DW. Plasma homocysteine is a risk factor for recurrent vascular events in young patients with an ischemic stroke or TIA. J Neurol 2005;152:332-7.   Back to cited text no. 1    
2.Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004;109:2766-72.   Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 2003;34:1258-61.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Toole JE, Malinow MR, Chambless LE, Spence JD, Howard VJ, Sides EG, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA 2004;291:565-75.   Back to cited text no. 4    
5.Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81   Back to cited text no. 5  [PUBMED]  [FULLTEXT]
6.Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 2005;5:215-22.  Back to cited text no. 6  [PUBMED]  




 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow